Search

Displaying results 5001 - 5010 of 10000 in total
  1. Drug

    Yttrium Y-90

    go.drugbank.com/drugs/DB13076
    ApprovedInvestigational

    Yttrium 90 has been investigated for the treatment of Colon Cancer and Colorectal Cancer.

  2. Drug

    Desomorphine

    go.drugbank.com/drugs/DB01531
    ExperimentalIllicit

    Categories: Heterocyclic Compounds with 4 or More Rings
  3. Drug

    Dichloralphenazone

    go.drugbank.com/drugs/DB01495
    ApprovedIllicit

    Dichloralphenazone is a sedative composed of chloral hydrate and phenazone. … It is typically found in combination products Nodolor and Midrin containing [isometheptene] and [acetaminophen] used for the relief of tension and vascular headaches.

  4. Drug

    Denufosol

    go.drugbank.com/drugs/DB04983
    Investigational

    The drug was also evaluated in the treatment of retinal detachment and other diseases of the retina. Denufosol has not gained FDA approval, and clinical trials with this drug have ceased since 2011. … Denufosol was an inhaled drug used for the treatment of cystic fibrosis (CF), showing various improvements in lung function during a phase III clinical trial.

  5. Drug

    Ezatiostat

    go.drugbank.com/drugs/DB05460
    Investigational

    atom of another. … These are compounds containing an amide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen

  6. Drug

    KW-7158

    go.drugbank.com/drugs/DB05498
    Experimental

    (involuntary abnormal contraction of the bladder). … KW-7158 is a tricyclic compound with a non-cholingergic mechanism of action for the treatment of "urinary urgency," "frequent urination" and "urinary incontinence" associated with bladder overactivity

  7. Drug

    Selatogrel

    go.drugbank.com/drugs/DB15163
    Investigational

    Selatogrel is under investigation in clinical trial NCT03814200 (A Study to Investigate the Effect of Rifampicin on the Uptake and Breakdown of ACT-246475 in Healthy Subjects).

  8. Drug

    PW2101

    go.drugbank.com/drugs/DB06483
    Experimental

    The development of PW2101 has since been discontinued. … The drug was developed by Penwest Pharmaceuticals and in 2005 the FDA issues a Non-Approval letter due to the degree of kinetic variability of PW2101 observed among individuals.

  9. Drug

    Flurocitabine

    go.drugbank.com/drugs/DB20317
    Experimental

    The usage of the INN stem '-citabine' in the name indicates that Flurocitabine is a nucleoside antiviral or antineoplastic agent, cytarabine or azacitidine derivative. … Flurocitabine has a monoisotopic molecular weight of 243.07 Da.

  10. Drug

    Emricasan

    go.drugbank.com/drugs/DB05408
    Investigational

    Emricasan is the first caspase inhibitor tested in human which has received orphan drug status by FDA. It is developed by Pfizer and made in such a way that it protects liver cells from excessive apoptosis.